Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Change in Accured Expenses: 2015-2024

Historic Change in Accured Expenses for Corvus Pharmaceuticals (CRVS) over the last 10 years, with Dec 2024 value amounting to -$245,000.

  • Corvus Pharmaceuticals' Change in Accured Expenses rose 895.51% to $708,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 537.79%. This contributed to the annual value of -$245,000 for FY2024, which is 93.15% up from last year.
  • As of FY2024, Corvus Pharmaceuticals' Change in Accured Expenses stood at -$245,000, which was up 93.15% from -$3.6 million recorded in FY2023.
  • In the past 5 years, Corvus Pharmaceuticals' Change in Accured Expenses registered a high of $705,000 during FY2020, and its lowest value of -$3.6 million during FY2023.
  • Over the past 3 years, Corvus Pharmaceuticals' median Change in Accured Expenses value was -$245,000 (recorded in 2024), while the average stood at -$1.1 million.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first surged by 189.29% in 2022, then crashed by 866.17% in 2023.
  • Corvus Pharmaceuticals' Change in Accured Expenses (Yearly) stood at $705,000 in 2020, then plummeted by 174.18% to -$523,000 in 2021, then surged by 189.29% to $467,000 in 2022, then crashed by 866.17% to -$3.6 million in 2023, then soared by 93.15% to -$245,000 in 2024.